A Multicenter Phase II Study of Local Radiation Therapy for Stage IEA Mucosa-Associated Lymphoid Tissue Lymphomas: A Preliminary Report From the Japan Radiation Oncology Group (JAROG)

Isobe, Koichi; Kagami, Yoshikazu; Higuchi, Keiko; Kodaira, Takeshi; Hasegawa, Masatoshi; Shikama, Naoto; Nakazawa, Masanori; Fukuda, Ichiro; Nihei, Keiji; Ito, Kana; Teshima, Teruki; Matsuno, Yoshihiro; Oguchi, Masahiko

doi:10.1016/j.ijrobp.2007.04.029

« Previous Next »International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1181-1186, 15 November 2007

A Multicenter Phase II Study of Local Radiation Therapy for Stage IEA Mucosa-Associated Lymphoid Tissue Lymphomas: A Preliminary Report From the Japan Radiation Oncology Group (JAROG)

Koichi Isobe, M.D.
- Department of Radiology, Chiba University Hospital, Chiba, Japan
- Reprint requests to: Koichi Isobe, M.D., Department of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. Tel: (+81) 43-226-2100; Fax: (+81) 43-226-2101
Yoshikazu Kagami, M.D.
- Radiation Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Keiko Higuchi, M.D.
- Department of Radiology, Gunma Prefecture Cancer Center, Gunma, Japan
Takeshi Kodaira, M.D.
- Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi, Japan
Masatoshi Hasegawa, M.D.
- Department of Radiation Oncology, Nara Medical University, Nara, Japan
Naoto Shikama, M.D.
- Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan
Masanori Nakazawa, M.D.
- Department of Radiology, Jichi Medical University, Tochigi, Japan
Ichiro Fukuda, M.D.
- Department of Radiology, Jikei University School of Medicine, Tokyo, Japan
Keiji Nihei, M.D.
- Radiation Oncology Division, National Cancer Center Hospital East, Chiba, Japan
Kana Ito, M.D.
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
Teruki Teshima, M.D.
- Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Osaka, Japan
Yoshihiro Matsuno, M.D.
- Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
Masahiko Oguchi, M.D.
- Department of Radiologic Oncology, Cancer Institute Hospital, Tokyo, Japan

Received 6 March 2007; received in revised form 17 April 2007; accepted 18 April 2007. published online 04 July 2007.

Purpose

The aim of this study was to evaluate the efficacy and toxicity of moderate dose radiation therapy (RT) for mucosa-associated lymphoid tissue (MALT) lymphoma in a prospective multicenter phase II trial.

Methods and Materials

The subjects in this study were 37 patients with MALT lymphoma between April 2002 and November 2004. There were 16 male and 21 female patients, ranging in age from 24 to 82 years, with a median of 56 years. The primary tumor originated in the orbit in 24 patients, in the thyroid and salivary gland in 4 patients each, and 5 in the others. The median tumor dose was 30.6 Gy (range, 30.6–39.6 Gy), depending on the primary site and maximal tumor diameter. The median follow-up was 37.3 months.

Results

Complete remission (CR) or CR/unconfirmed was achieved in 34 patients (92%). The 3-year overall survival, progression-free survival, and local control probability were 100%, 91.9%, and 97.3%, respectively. Thirteen patients experienced Grade 1 acute toxicities including dermatitis, mucositis, and conjunctivitis. One patient developed Grade 2 taste loss. Regarding late toxicities, Grade 2 reactions including hypothyroidism, and radiation pneumonitis were observed in three patients, and Grade 3 cataract was seen in three patients.

Conclusions

This prospective phase II study demonstrated that moderate dose RT was highly effective in achieving local control with acceptable morbidity in 37 patients with MALT lymphoma.

MALT lymphoma, Radiation therapy, Local control, Acute toxicity, Late adverse event